TokenPost topic
1 TokenPost story is tagged Relacorilant. The newest appear first.
The current Cushing’s syndrome business could generate at least $2 billion in annual revenue by decade’s end. The FDA is expected to decide on relacorilant by Dec. 17, 2026.
Nov 4, 2026, 6:44 AM EST · Business
